A Phase 2 Clinical Study of ABSK061 and ABSK043

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(21 sites)

China

Guizhou Provincial People'S Hospital, Guiyang, Guizhou

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Heibei

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Central Hospital, Changsha, Hunan

Jiangxi Cance Hospital, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Cancer Hospital of Shandong First Medical University, Jinan, Shandong

ZhongShan Hospital Fudan University, Shanghai, Shanghai Municipality

Xiangyang Central Hospital, Xiangyang, Sichuang

Changzhi People's Hospital, Changzhi

West China Hospital, Sichuan University, Chengdu

The First Hospital of China Medical University, Hangzhou

Zhejiang Provincial People'S Hospital, Hangzhou

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

First Hospital of Shanxi Medical University, Xi'an

Shanxi Cancer hospital (Shanxi Cancer institute), Xi'an

First Affiliated Hospital of Xiamen University, Xiamen

The Affiliated Hospital of Xuzhou Medical University, Xuzhou